Vivanza Biosciences Ltd

Vivanza Biosciences Ltd (VIVANZA) is a micro-cap Healthcare company valued at ₹7 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Vivanza Biosciences Ltd last traded at ₹1.69, modestly down 0.59% on the day.

Recent developments

On 2026-09-30, the promoter holding was recorded at 20.02%, with no changes noted in foreign or domestic institutional holdings. The company's financials show a high debt to equity ratio of 2.34, indicating significant leverage.

Financial performance

The company's revenue surged 1462.1% annually, but net profit remained at ₹0 crore, swinging from a net loss of ₹1 crore to a profit of ₹0 crore. The latest quarter showed revenue growth of 3.9% compared to the same quarter a year earlier, while net profit increased 66.7% to ₹0 crore.

Valuation multiples

The stock trades at 16.9 times earnings, a discount to the Healthcare median of 32.0, 1.73 times book value.

Things to watch

The company has a high debt to equity ratio of 2.34, which increases financial risk. The stock is 37.5% below its 52-week high, reflecting a decline in price. The company's net profit margin improved to 0.3% from -9.1%, but net profit remains at ₹0 crore.

Where it stands

The company's revenue has grown rapidly, but net profit remains at zero. The stock is 37.5% below its 52-week high, and the company has a high debt to equity ratio of 2.34. The latest quarter revenue was ₹9 crore, with net profit at ₹0 crore.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.